Skip to main content Accessibility help
×
Home

The Netherlands

  • David Banta (a1) and Wija J. Oortwijn (a2)

Abstract

Objective: The aim of this report was to describe the history of health technology assessment (HTA) in the Netherlands.

Methods: This article is a descriptive review from two people who have been very much involved in the events described and is based on review of relevant policy documents and Web sites.

Results: HTA has been progressively developed in the Netherlands since (at least) the early 1980s. Beginning in 1985, there were progressive attempts to expand and institutionalized HTA in the Netherlands healthcare system. These attempts were generally successful, but did not result in a national agency for HTA. An important development in HTA in the Netherlands was a special fund (Ontwikkelingsgeneeskunde) designed to support prospective HTAs with the main purpose of affecting insurance coverage decisions. The administration of this fund moved progressively to broaden the subjects chosen for analysis to include such subjects as chronic illness and disability. A more-or-less hidden conflict developed in the question of the leadership and orientation of this fund, with the result that it was largely moved to a more research-oriented and less policy-oriented site.

Conclusions: The situation today is that HTA is visible and is used by the government in policy decisions, especially in the areas of prevention and screening. In addition, HTA is influential in insurance coverage decision making, especially in the field of pharmaceuticals. The principles of HTA and evidence-based medicine are generally familiar to physicians and other clinicians, however, the influence of HTA on clinical and administrative decisions is less than in some other countries.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The Netherlands
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The Netherlands
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The Netherlands
      Available formats
      ×

Copyright

References

Hide All
1.Banta, HD, Oortwijn, W. Health technology assessment and screening in the Netherlands: Case studies of mammography in breast cancer, PSA screening in prostate cancer, and ultrasound in normal pregnancy. Int J Technol Assess Health Care. 2001;17:369377.
2.Banta, HD, Oortwijn, WJ, Van Beekum, WT. The organization of health care technology assessment in the Netherlands. The Hague: The Rathenau Institute; 1995.
3.Banta, D, Gelijns, A, eds. Anticipating and assessing health care technology. vol. 1. General considerations and policy conclusions. Dordrecht: Martinus Nijhoff Publishers; 1987.
4.Bos, M. Health care technology in the Netherlands. In: Health care technology and its assessment in eight countries. Washington, DC: US Government Printing Office; 1995:171208.
5.Canadian Coordinating Office for Health Technology Assessment. Guide for economic evaluation of pharmaceuticals. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997.
6.College voor zorgverzekeringen (Health Care Insurance Board). Richtlijnen voor farmacoeconomische onderzoek [Dutch guidelines for pharmacoeconomic research]. Amstelveen: College voor zorgverzekeringen; 1999.
7.De Wolf, P, Brouwer, WB, Rutten, FF. Regulating the Dutch pharmaceutical market: Improving efficiency or controlling costs? Int J Health Plann Manage. 2005;20:351374.
8.Dunning, A. Committee on choices in health care (Kiezen en Delen). Rijswijk: Ministry of Health; 1991.
9.Health Council. Medical practice at the crossroads. The Hague: Health Council; 1996.
10.Health Insurance Council. Assessment of the benefits package regarding pharmaceuticals. Publication 680. Amstelveen: Ziekenfondsraad; 1997.
11.Institute for Medical Technology Assessment (iMTA). The costs and effects of mass screening for breast cancer. Rotterdam: Erasmus University Rotterdam; 1987.
12.Mastenbroek, CG, Van Der Meer, FM, Zwaap, J, Fikken, F, Polman, MPH. Pakketbeheer in de praktijk. Diemen: College voor zorgverzekeringen; 2006.
13.Ministry of Health. Law on population screening. Rijswijk: Ministry of Health; 1996.
14.Ministry of Health. Prevention. http://www.minvws.nl/en/themes/prevention/default.asp (accessed September 2008).
15.Ministry of Health. Progress report on medical technology assessment and cost-effectiveness of care. Rijswijk: Ministry of Health, Welfare and Sport; 1997.
16.Ministry of Health. The new care system in the Netherlands (in three languages). http://www.minvws.nl/en/folders/z/2006/the-new-health-insurance-system-in-three-languages.asp (accessed September 2008).
17.Oortwijn, W, Hanney, SH, Ligtvoet, A, et al. Assessing the impact of health technology assessment in the Netherlands. Int J Technol Assess Health Care. 2008;4:259269.
18.Oostenbrink, JB, Bouwmans, CAM, Koopmanschap, MA, Rutten, FFH. Handleiding voor kostenonderzoek: Methoden en richtlijnprijzen voor economische evaluatie in de gezondheidszorg [Manual for costing research: Methods and reference prices for economic evaluation in healthcare]. Amstelveen: College voor zorgverzekeringen; 2004.
19.Rigter, H. Assessment of health care technology in the Netherlands. In: Banta, D, Luce, B, eds. Health care technology and its assessment. Oxford: Oxford University Press; 1993:213222.
20.Toenders, WGM. Breedte geneesmiddelenpakket [Breadth of the benefits package regarding pharmaceuticals]. Amstelveen: College voor zorgverzekeringen; 2001.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed